These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 10543335)

  • 21. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
    Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
    Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of tolterodine in children after oxybutynin failure.
    Bolduc S; Upadhyay J; Payton J; Bägli DJ; McLorie GA; Khoury AE; Farhat W
    BJU Int; 2003 Mar; 91(4):398-401. PubMed ID: 12603422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity.
    Guay DR
    Pharmacotherapy; 1999 Mar; 19(3):267-80. PubMed ID: 10221366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
    Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
    Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
    Freeman R; Hill S; Millard R; Slack M; Sutherst J;
    Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.